Para realizar su inscripción, haga clic en el botón a continuación y complete sus datos
Quiero inscribirmeCOSTO DE INSCRIPCIÓN
Socio AAMR con cuota al día al 31/03/2026 - SIN CARGO
No socios - AR$ 80.000
Residentes - Enfermeros - Técnicos - SIN CARGO
INVITADOS INTERNACIONALES
Dra. Noemí Reguart
España
Dra. Noemí Reguart
España
Dr. Noemi Reguart graduated from the University of Medicine Lleida in 1995. She
then finished her postgraduate studies and oncology fellowship at the Hospital Clinic
in Barcelona (2001). She earned a PhD in molecular lung cancer during her predoctoral
work at the University of California, San Francisco (2004–2005). She has been working as a thoracic oncologist at the Hospital Clinic Barcelona's Department of
Medical Oncology since 2008. In addition, she is an Associate Professor at the University of Barcelona's School of Medicine, where she is committed to both undergraduate and graduate education. Dr. Reguart has been instrumental in the development and institutional recognition of the Thoracic Oncology Unit, at the Hospital Clinic, which she is in charge of as of the year 2020.
Lung cancer research has always been a top goal for Dr. Reguart. She accomplishes this by combining her usual duties and patient care with translational research. She has taken part in a variety of trials investigating cutting-edge therapies for people with lung cancer, including their design and patient enrollment. She also oversees a Thoracic Research Group, part of the Translational Genomics and Targeted Therapeutics in Solid Tumors Lab at the August Pi i Sunyer Biomedical Research Institute (IDIBAPS), that is tasked with finding new biomarkers that could be used as lung cancer predictive indicators and as a gauge of treatment response. Working with other teams undertaking groundbreaking research, she specifically integrates and assesses cutting-edge technology to ensure that it can be properly translated in the clinic.
Dr. Reguart has authorship on numerous publications in the field of NSCLC and targeted medicine, is co-author of several national and international guidelines for the treatment of lung cancer and is an active opinion leader on networks (Twitter@NReguart). Prof. Reguart holds memberships in several national and international scientific organizations including the Spanish Lung Cancer Group (SLCG), the Spanish Association for Cancer Research (ASEICA), the European Organization for Research and Treatment of Cancer (EORTC), the European Society for Medical Oncology (ESMO), and the International Association for the Study of Lung Cancer (IASLC) (all currently actives). She is currently chair of the EORTC Lung Cancer Group for Small Cell Lung Cancer (2021-) and Committee Member for the IASLC Communications Committee (2019-). She also served as a member of the Board of Directors of the SLCG (2007–2019), Faculty Member of ESMO (2021-) and ASEICA (2014-2018). She has been invited to join various national and international conferences’ scientific committees (ASEICA, SLCG, WCLC, ELCC, ESMO), several working groups (i.e., Oncology-PRO Working Group, ESMO), and has served as both a guest speaker and keynote speaker at numerous national and international conferences. Dr. Reguart has chaired the ELCC 2023 and IASLC-WCLC 2025. Dr. Reguart is a referee or reviewer for several indexed international journals and competitive national and international research calls.
Dr. Sergio Call
España
Dr. Sergio Call
España
Sergi Call nació en Barcelona en 1979 y se licenció en Medicina por la Universidad Autónoma de Barcelona en 2003. Realizó la especialidad de Cirugía Torácica en el Hospital Universitario
MútuaTerrassa, donde obtuvo el título de especialista en 2010.
Es Profesor Asociado de Anatomía en la Universidad Autónoma de Barcelona desde 2014 y Profesor Asociado de Cirugía Torácica en la Universidad de Barcelona desde 2020. En 2017 obtuvo el grado de Doctor por la Universidad de Barcelona, con la tesis titulada “Estadificación y reestadificación prequirúrgica de máxima certeza en el tratamiento quirúrgico del carcinoma broncogénico”, calificada con Sobresaliente Cum Laude.
Desarrolla su actividad asistencial como cirujano torácico en el Hospital Universitario MútuaTerrassa, donde actualmente ejerce como Jefe Clínico del Servicio de Cirugía Torácica. Cuenta con la acreditación como Fellow del European Board of Thoracic and Cardiovascular Surgeons por la European Union of Medical Specialists (UEMS), y participa activamente en sociedades científicas nacionales e internacionales.
Sus principales áreas de interés incluyen la estadificación quirúrgica del cáncer de pulmón, la cirugía mínimamente invasiva, las metástasis pulmonares y la oncología torácica. Es autor de más de 20 capítulos de libro en el ámbito de la cirugía torácica y la oncología torácica, así como autor o coautor de más de 50 publicaciones en revistas internacionales indexadas.
Dr. Juan P. Wisnivesky
Estados Unidos
Dr. Juan Pablo Wisnivesky
Estados Unidos
Juan Pablo Wisnivesky is the Drs. Richard and Mortimer Bader Professor of Medicine and Chief of the Division of General Internal Medicine at the Icahn School of Medicine at Mount Sinai in New York City. An experienced health services researcher, Dr. Wisnivesky’s work focuses on lung cancer epidemiology, lung cancer screening, and patient-oriented outcomes. He earned his MD from the University of Buenos Aires School of Medicine and his MPH and Doctor of Public Health degree from the Joseph L. Mailman School of Public Health at Columbia University in New York City.
Dr. Wisnivesky has been awarded numerous grants from the National Institutes of Health and the Agency for Healthcare Research and Quality to support his research. He serves as the director of a federally funded Cancer Prevention and Control T32 Training Program, which focuses on improving cancer prevention and outcomes among priority populations. His research utilizes large national datasets and administrative claims data to investigate the epidemiology, diagnosis, treatment, and outcomes of lung cancer.
Dr. Wisnivesky is engaged in global research education as faculty in the American Thoracic Society’s Methods in Epidemiologic, Clinical, and Operations Research Program, which trains early-career investigators across Latin America. Additionally, he is an active member of the American Society for Clinical Investigation and is a member of the National Committee on Vital and Health Statistics.
Dr. Ignacio Wistuba
Estados Unidos
Dr. Ignacio Wistuba
Estados Unidos
Ignacio I. Wistuba, MD, is Chair and Senior Member of the Department of Translational Pathology at Moffitt Cancer Center, Tampa, Florida, USA. Until May 2025, he was Professor and Chair of the Department of Translational Molecular Pathology with joint appointment in the Department of Thoracic/Head and Neck Medical Oncology, and co-director of the Institute of Personalized Cancer Therapy (IPCT) at the University of Texas MD Anderson Cancer Center. Between 2019 and 2022 he served as Head of the Division of Pathology and Laboratory Medicine at MD Anderson. He is a member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC).
Dr. Wistuba’s major research interest is the elucidation of the molecular abnormalities involved in the pathogenesis and progression of lung cancer and other solid tumors. He has co-authored over 850 papers in peer-reviewed journals and several book chapters. He led several extramural peer-review funded (NCI, DoD, V-Foundation, and Texas CPRIT) programmatic research programs. His research interests also include identifying new molecular targets, validating biomarkers for targeted therapy and immunotherapy, and identifying molecular markers associated with lung cancer and other solid tumors development, progression and metastasis development using annotated human specimens.
PROGRAMA
08:00 - 08:30hs. (UTC-3)
ACREDITACIÓN
08:50 - 09:00hs. (UTC-3)
APERTURA – PALABRAS DE BIENVENIDA
Dr. Carlos Brescacin
Presidente AAMR
Dres. José Menéndez y Claudio Martín
Comité Organizador
08:50 - 09:20hs. (UTC-3)
IMPACTO DE LAS NUEVAS SUBCATEGORÍAS N2A Y N2B EN LA ESTADIFICACIÓN PREQUIRÚRGICA
Disertante: DR. Sergi Call
09:10 - 09:20hs. (UTC-3)
Discusión y Preguntas
09:20 - 09:50hs. (UTC-3)
NEUMONÓLOGO 1. EPOC Y CANCER DE PULMÓN. NO SÓLO UNA COINCIDENCIA.
Disertantes: Dr. Juan Pablo Wisnivesky
09:40 - 09:50hs. (UTC-3)
Discusión y Preguntas
09:50 - 10:20hs. (UTC-3)
ESTADO ACTUAL DE LA IO PERIOPERATORIA
Disertante: Dra. Noemi Reguart
10:10 - 10:20hs. (UTC-3)
Discusión y Preguntas
10:20 - 10:50hs. (UTC-3)
COFFEE BREAK
10:50 - 11:50hs. (UTC-3)
SIMPOSIO ROCHE
11:50 - 12:20hs. (UTC-3)
ROL DEL PATÓLOGO EN EL TRATAMIENTO NEOADYUVANTE EN CANCER DE PULMÓN
Disertante: Dr. Ignacio Wistuba
12:10 - 12:20hs. (UTC-3)
Discusión y Preguntas
12:20 - 12:50hs. (UTC-3)
CRIBAJE EN CÁNCER DE PULMÓN CON COMORBILIDADES
Disertante: Dr. Juan Pablo Wisnivesky
12:40 - 12:50hs. (UTC-3)
Discusión y Preguntas
12:50 - 13:50hs. (UTC-3)
Simposio AstraZeneca
14:00 - 14:30hs. (UTC-3)
VAMLA: TÉCNICAS E INDICACIONES
Disertante: Dr. Sergi Call
14:20 - 14:30hs. (UTC-3)
Discusión y Preguntas
14:30 - 15:00hs. (UTC-3)
TRATAMIENTO RADIANTE EN PACIENTES CON CANCER DE PULMÓN OLIGOMETASTÁSICO
Disertante: Dr. Matías Zapata
15:00 - 15:30hs. (UTC-3)
Conferencia MSD
15:30 - 16:00hs. (UTC-3)
COFFEE BREAK
16:00 - 16:15hs. (UTC-3)
CIRUGÍA ROBÓTICA. MITO O REALIDAD
16:15 - 17:00hs. (UTC-3)
DISCUSIÓN DE CASOS CLÍNICOS. TERAPIAS
Disertantes: Dra. Noemi Reguart - Dr. Sergi Call - Dr. Juan Pablo Wisnivesky - Dr. Ignacio Wistuba
Cierre de jornada
08:30 - 09:00hs. (UTC-3)
ACREDITACIÓN
09:00 - 09:30hs. (UTC-3)
OPCIONES TERAPÉUTICAS PARA EL CÁNCER DE PULMÓN ESTADIO I
Disertante: Dr. Juan Pablo Wisnivesky
09:20 - 09:30hs. (UTC-3)
Discusión y Preguntas
09:30 - 10.00hs. (UTC-3)
RECOMENDACIONES SEPAR / SECT SOBRE ESTADIFICACIONES INVASIVA MEDIASTÍNICA PERIOPERATORIA
Disertante: Dr. Sergi Call
09:50 - 10:00hs. (UTC-3)
Discusión y Preguntas
10:00 - 10:30hs. (UTC-3)
COFFEE BREAK
10:30 - 11:00hs. (UTC-3)
NOVEDADES EN EL MANEJO DE LOS PACIENTES CON SCLC
Disertante: Dra. Noemí Reguart
10:50 - 11:00hs. (UTC-3)
Discusión y Preguntas
11:00 - 12:00hs. (UTC-3)
SIMPOSIO ASTRAZENECA
12:00 - 12:30hs. (UTC-3)
PARTICIPACIÓN DE LA IA EN EL DIAGNÓSTICO MOLECULAR
Disertante: Dr. Ignacio Wistuba
12:20 - 12:30hs. (UTC-3)
Discusión y Preguntas
12:30 - 13:30hs. (UTC-3)
SIMPOSIO JANSSEN
13:40 - 14:10hs. (UTC-3)
CÁNCER DE PULMÓN EN PACIENTES CON HIV
Disertante: Dr. Juan Pablo Wisnivesky
14:00 - 14:10hs. (UTC-3)
Discusión y Preguntas
14:10 - 14:40hs. (UTC-3)
BIOPSIA LÍQUIDA EN EL MANEJO DEL CÁNCER DE PUMÓN PRESENTE Y FUTURO
Disertante: Dr. Ignacio Wistuba
14:30 - 14:40hs. (UTC-3)
Discusión y Preguntas
14:40 - 15:10hs. (UTC-3)
Conferencia
Disertante: Dr. Juan Manuel Lucchelli
15:00 - 15:10hs. (UTC-3)
Discusión y Preguntas
15:10 - 15:40hs. (UTC-3)
COFFEE BREAK
15:40 - 16:10hs. (UTC-3)
OPCIONES DE TRATAMIENTO LUEGO DE QUIMIOTERAPIA MAS INMUNOTERAPIA EN CPNCP SIN DRIVERS
Disertante: Dra. Noemí Reguart
16:00 - 16:10hs. (UTC-3)
Discusión y Preguntas
16:10 - 17:10hs. (UTC-3)
DISCUSIÓN DE CASOS CLÍNICOS. COMITÉ MOLECULAR
Disertantes: Dra. Noemi Reguart - Dr. Sergi Call - Dr. Juan Pablo Wisnivesky - Dr. Ignacio Wistuba
CLAUSURA
COMITÉ ORGANIZADOR y CIENTÍFICO
SPONSORS
AUSPICIOS ACADÉMICOS
